Hepatic processing of transforming growth factor β in the rat

Uptake, metabolism, and biliary excretion

R. J. Coffey, L. J. Kost, R. M. Lyons, H. L. Moses, Nicholas F La Russo

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Transforming growth factor beta (TGFβ), a recently discovered polypeptide, modulates growth of normal and neoplastic cells. Since little is known concerning in vivo disposition of TGFβ, we performed studies to examine the hepatic processing of biologically active 125I-TGFβ in the rat. After intravenous injection, 125I-TGFβ disappeared from the plasma with an initial t( 1/2 ) of 2.2 min; partial hepatectomy delayed the plasma disappearance of 125I-TGFβ by 80%. 60 min after intrafemoral injection, 63% of the recovered label was present in liver and/or bile; by 90 min, most of the label removed by the liver (83%) had been slowly excreted into bile. Nearly all the label in bile (96%) was soluble in trichloracetic acid and not immunoprecipitable by specific antiserum. Colchicine and vinblastine inhibited cumulative biliary excretion of label by 28 and 37%, respectively; chloroquine and leupeptin each increased the amount of label in bile that was precipitable by trichloracetic acid and that coeluted with authentic 125I-TGFβ on molecular sieve chromatography. There was efficient first-pass hepatic extraction of 125I-TGFβ (36%) in the isolated perfused rat liver, which was inhibited by unlabeled TGFβ (but not by epidermal growth factor, EGF) and by lectins in a dose-dependent manner; prolonged fasting also decreased clearance (26%). After fractionation of liver by differential or isopycnic centrifugation, radiolabel codistributed with marker enzymes for lysosomes. The results indicate rapid, extensive, inhibitable, and organ-selective extraction of TGFβ by the liver. After extraction, TGFβ undergoes efficient transhepatic transport, extensive intracellular metabolism, and slow but complete biliary excretion of its metabolites. Liver fractionation studies and pharmacologic manipulations suggest that these processes are associated with organelles that include microtubules and lysosomes. The data suggest that the liver is a major target tissue or site of metabolism for biologically active TGFβ.

Original languageEnglish (US)
Pages (from-to)750-757
Number of pages8
JournalJournal of Clinical Investigation
Volume80
Issue number3
StatePublished - 1987

Fingerprint

Transforming Growth Factors
Transforming Growth Factor beta
Liver
Bile
Lysosomes
Hepatobiliary Elimination
Isopycnic Centrifugation
Acids
Vinblastine
Chloroquine
Colchicine
Hepatectomy
Epidermal Growth Factor
Lectins
Intravenous Injections
Microtubules
Organelles
Gel Chromatography
Immune Sera
Fasting

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatic processing of transforming growth factor β in the rat : Uptake, metabolism, and biliary excretion. / Coffey, R. J.; Kost, L. J.; Lyons, R. M.; Moses, H. L.; La Russo, Nicholas F.

In: Journal of Clinical Investigation, Vol. 80, No. 3, 1987, p. 750-757.

Research output: Contribution to journalArticle

@article{2b042d84335e4d8baf903cd595fbee8e,
title = "Hepatic processing of transforming growth factor β in the rat: Uptake, metabolism, and biliary excretion",
abstract = "Transforming growth factor beta (TGFβ), a recently discovered polypeptide, modulates growth of normal and neoplastic cells. Since little is known concerning in vivo disposition of TGFβ, we performed studies to examine the hepatic processing of biologically active 125I-TGFβ in the rat. After intravenous injection, 125I-TGFβ disappeared from the plasma with an initial t( 1/2 ) of 2.2 min; partial hepatectomy delayed the plasma disappearance of 125I-TGFβ by 80{\%}. 60 min after intrafemoral injection, 63{\%} of the recovered label was present in liver and/or bile; by 90 min, most of the label removed by the liver (83{\%}) had been slowly excreted into bile. Nearly all the label in bile (96{\%}) was soluble in trichloracetic acid and not immunoprecipitable by specific antiserum. Colchicine and vinblastine inhibited cumulative biliary excretion of label by 28 and 37{\%}, respectively; chloroquine and leupeptin each increased the amount of label in bile that was precipitable by trichloracetic acid and that coeluted with authentic 125I-TGFβ on molecular sieve chromatography. There was efficient first-pass hepatic extraction of 125I-TGFβ (36{\%}) in the isolated perfused rat liver, which was inhibited by unlabeled TGFβ (but not by epidermal growth factor, EGF) and by lectins in a dose-dependent manner; prolonged fasting also decreased clearance (26{\%}). After fractionation of liver by differential or isopycnic centrifugation, radiolabel codistributed with marker enzymes for lysosomes. The results indicate rapid, extensive, inhibitable, and organ-selective extraction of TGFβ by the liver. After extraction, TGFβ undergoes efficient transhepatic transport, extensive intracellular metabolism, and slow but complete biliary excretion of its metabolites. Liver fractionation studies and pharmacologic manipulations suggest that these processes are associated with organelles that include microtubules and lysosomes. The data suggest that the liver is a major target tissue or site of metabolism for biologically active TGFβ.",
author = "Coffey, {R. J.} and Kost, {L. J.} and Lyons, {R. M.} and Moses, {H. L.} and {La Russo}, {Nicholas F}",
year = "1987",
language = "English (US)",
volume = "80",
pages = "750--757",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Hepatic processing of transforming growth factor β in the rat

T2 - Uptake, metabolism, and biliary excretion

AU - Coffey, R. J.

AU - Kost, L. J.

AU - Lyons, R. M.

AU - Moses, H. L.

AU - La Russo, Nicholas F

PY - 1987

Y1 - 1987

N2 - Transforming growth factor beta (TGFβ), a recently discovered polypeptide, modulates growth of normal and neoplastic cells. Since little is known concerning in vivo disposition of TGFβ, we performed studies to examine the hepatic processing of biologically active 125I-TGFβ in the rat. After intravenous injection, 125I-TGFβ disappeared from the plasma with an initial t( 1/2 ) of 2.2 min; partial hepatectomy delayed the plasma disappearance of 125I-TGFβ by 80%. 60 min after intrafemoral injection, 63% of the recovered label was present in liver and/or bile; by 90 min, most of the label removed by the liver (83%) had been slowly excreted into bile. Nearly all the label in bile (96%) was soluble in trichloracetic acid and not immunoprecipitable by specific antiserum. Colchicine and vinblastine inhibited cumulative biliary excretion of label by 28 and 37%, respectively; chloroquine and leupeptin each increased the amount of label in bile that was precipitable by trichloracetic acid and that coeluted with authentic 125I-TGFβ on molecular sieve chromatography. There was efficient first-pass hepatic extraction of 125I-TGFβ (36%) in the isolated perfused rat liver, which was inhibited by unlabeled TGFβ (but not by epidermal growth factor, EGF) and by lectins in a dose-dependent manner; prolonged fasting also decreased clearance (26%). After fractionation of liver by differential or isopycnic centrifugation, radiolabel codistributed with marker enzymes for lysosomes. The results indicate rapid, extensive, inhibitable, and organ-selective extraction of TGFβ by the liver. After extraction, TGFβ undergoes efficient transhepatic transport, extensive intracellular metabolism, and slow but complete biliary excretion of its metabolites. Liver fractionation studies and pharmacologic manipulations suggest that these processes are associated with organelles that include microtubules and lysosomes. The data suggest that the liver is a major target tissue or site of metabolism for biologically active TGFβ.

AB - Transforming growth factor beta (TGFβ), a recently discovered polypeptide, modulates growth of normal and neoplastic cells. Since little is known concerning in vivo disposition of TGFβ, we performed studies to examine the hepatic processing of biologically active 125I-TGFβ in the rat. After intravenous injection, 125I-TGFβ disappeared from the plasma with an initial t( 1/2 ) of 2.2 min; partial hepatectomy delayed the plasma disappearance of 125I-TGFβ by 80%. 60 min after intrafemoral injection, 63% of the recovered label was present in liver and/or bile; by 90 min, most of the label removed by the liver (83%) had been slowly excreted into bile. Nearly all the label in bile (96%) was soluble in trichloracetic acid and not immunoprecipitable by specific antiserum. Colchicine and vinblastine inhibited cumulative biliary excretion of label by 28 and 37%, respectively; chloroquine and leupeptin each increased the amount of label in bile that was precipitable by trichloracetic acid and that coeluted with authentic 125I-TGFβ on molecular sieve chromatography. There was efficient first-pass hepatic extraction of 125I-TGFβ (36%) in the isolated perfused rat liver, which was inhibited by unlabeled TGFβ (but not by epidermal growth factor, EGF) and by lectins in a dose-dependent manner; prolonged fasting also decreased clearance (26%). After fractionation of liver by differential or isopycnic centrifugation, radiolabel codistributed with marker enzymes for lysosomes. The results indicate rapid, extensive, inhibitable, and organ-selective extraction of TGFβ by the liver. After extraction, TGFβ undergoes efficient transhepatic transport, extensive intracellular metabolism, and slow but complete biliary excretion of its metabolites. Liver fractionation studies and pharmacologic manipulations suggest that these processes are associated with organelles that include microtubules and lysosomes. The data suggest that the liver is a major target tissue or site of metabolism for biologically active TGFβ.

UR - http://www.scopus.com/inward/record.url?scp=0023473081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023473081&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 750

EP - 757

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -